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Abstract
Background: Human papillomavirus type 18 is the second most common cause of cervical cancer and is found in
7 to 20 % of cases of cervical cancer. The oncogenic potential of high-risk human papillomavirus is associated with
expression of early proteins E6 and E7. Due to long-term immunosuppressive therapy, renal transplant recipients
have a higher risk of developing persistent human papillomavirus infection.
Case presentation: A 29-year-old white woman from Latvia with chronic focal segmental glomerulosclerosis received
renal allograft transplantation and was prescribed immunosuppressive therapy with cyclosporine, prednisolone, and
mycophenolate mofetil. Two weeks after renal transplantation, her cervical swab was positive for human papillomavirus
consensus sequences. After 6 months, quantitative polymerase chain reaction showed a high viral load of 3,630,789
copies/105 cells of high-risk human papillomavirus type 18 and expression of E6 and E7 oncogenes in her cervical swab
and urine sample. One year after renal transplantation, the viral load in her cervical swab increased significantly to
7,413,102 copies/105 cells. Messenger ribonucleic acid of human papillomavirus type 18 E6 and E7 oncogenes were
also detected. Shortly after this, she had an unsuccessful pregnancy which resulted in a spontaneous abortion at 6/7
weeks. Two months after the abortion her viral load sharply decreased to 39 copies/105 cells. Oncogenes E6 and E7
messenger ribonucleic acid expression was not observed in this period.
Conclusions: This case report represents data which show that immunosuppressive therapy may increase the risk of
developing persistent high-risk human papillomavirus infection with expression of E6 and E7 oncogenes in renal
transplant recipients. However, even during this therapy the immune status of a recipient can improve and contribute
to human papillomavirus viral load reduction. Spontaneous abortion can be considered a possible contributory factor
in human papillomavirus clearance.
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Background
Cervical cancer is the second most common cancer
for women in the world. Human papillomavirus type
18 (HPV-18) is the second most common cause of
cervical cancer and is found in 7 to 20 % of cases of
cervical cancer [1]. The oncogenic potential of high-
risk (HR) human papillomavirus (HPV) is associated
with expression of early proteins E6 and E7. It has
been shown that the overexpression of E6 and E7
transcripts has a leading role in the progression of
the disease [2].
A clearance of HPV infection within 2 years happens
in 91 % of healthy immunocompetent individuals and
strongly depends on adequate immune response [3].
Due to long-term immunosuppressive therapy, renal
transplant recipients have faster progression from infec-
tion to lesions and a higher risk of developing cervical
cancer [4, 5].
* Correspondence: maksims.cistjakovs@rsu.lv
1August Kirchenstein Institute of Microbiology and Virology, Riga Stradins
University, Riga, Latvia
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cistjakovs et al. Journal of Medical Case Reports  (2016) 10:318 
DOI 10.1186/s13256-016-1090-5
Case presentation
The study was approved by the Ethics Committee of
Riga Stradiņš University, and written consent was
obtained from the patient.
During screening for HPV in Latvian renal transplant
recipients, a significant viral load of HR HPV-18 was
detected in a 29-year-old white woman’s vaginal swab
sample and it was taken for more detailed examination.
From cervical swabs and urine, her deoxyribonucleic
acid (DNA) and ribonucleic acid (RNA) were extracted
for further examination (at periods of 2 weeks, 6
months, 12 months, and 16 months after transplant-
ation). Her DNA was tested using standard polymerase
chain reaction (PCR) with consensus primers targeting
L1 region conservative for the majority of HPV types
[6]. The commercial HPV High Risk Screen Real-TM
Quant quantitative PCR (qPCR) kit (Sacace, Italy) was
used for quantitative detection of 12 types of HR HPV
(16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) in her
DNA samples extracted from cervical swabs and urine.
Reverse transcription PCR (RT-PCR) was used to find
messenger RNA (mRNA) of main HR HPV oncogenes:
E6 and E7. A peripheral blood sample was centrifuged
to obtain plasma for detection of immunoglobulin G
(IgG) against HR HPV major capsid’s protein L1 using
ELISA method (MyBioSource, USA). We also compared
absolute counts of CD3, CD4, CD8, CD16, CD19, CD38,
CD25, CD95 lymphocytes, and CD4/CD8 ratio progres-
sively (6 months, 12 months, and 16 months after
transplantation).
At the age of 8 years, she developed the first symp-
toms of a renal disease such as arterial hypertension,
edema, and proteinuria. After a renal biopsy she was
diagnosed with focal segmental glomerulosclerosis. In
2011 at the age of 25, she had cesarean section child-
birth. After the pregnancy her renal function worsened.
In March 2013 she started hemodialysis via an
arteriovenous fistula in her left forearm. When she was
scheduled in a waiting list for kidney transplantation (7
January 2013) she was informed and forewarned by a
nephrologist about pregnancy risks and advised to use
adequate contraception during immunosuppressive
therapy after transplantation.
On 28 September 2013 she was admitted to a hospital to
receive a renal transplantation from a deceased donor. The
donor’s human leukocyte antigen (HLA) was A3,6(28);
B7,44(12); DR11(5),13(6). Our patient’s HLA was A1,–;
B37,39(16); DR3,D11(5). Transplantation surgery was un-
complicated and she had primary graft function.
For induction immunosuppressive therapy she
received 20 mg of basiliximab (Simulect; Novartis, USA)
intravenously on the day of transplantation and on the
fourth day after transplantation. She was also adminis-
tered methylprednisolone (Solu-Medrol; Pfizer, USA)
intravenously for 4 days. On the day of transplantation
and on the first day after the operation, she was admin-
istered 500 mg of methylprednisolone (Solu-Medrol), on
the second day she was administered 250 mg, and on
the third day she was administered 125 mg of methyl-
prednisolone (Solu-Medrol).
She received prednisolone (Prednisolon; Gedeon
Richter, Hungary), mycophenolate mofetil (CellCept; F.
Hoffmann-La Roche, Switzerland), and cyclosporine
(Sandimmun Neoral; Novartis, USA) administered
orally. Her initial dosage of prednisolone was 30 mg
daily and over a period of 2 weeks the dosage was
gradually reduced to 20 mg per day. Her cyclosporine
dosage was increased from 100 mg twice a day to 175
mg twice a day, according to through levels of 49.4 to
133 ng/ml; mycophenolate mofetil was administered 2 g
daily.
After kidney transplantation she was directed to visit a
gynecologist to discuss adequate contraception during
immunosuppressive therapy. She was informed once
more that pregnancy is a contraindication during the
first 2 years after transplantation and/or while she is
receiving treatment with mycophenolate mofetil. On 14
October 2013 she was discharged from hospital with a
serum creatinine level of 120 mol/l. She was prescribed
the following maintenance immunosuppression therapy
(Fig. 1): prednisolone, 15 mg once a day; cyclosporine,
175 mg twice a day; and mycophenolate mofetil 500 mg
four times a day.
She was also prescribed 900 mg valganciclovir
(Valcyte; F. Hoffmann-La Roche, Switzerland) daily for
cytomegalovirus infection prophylaxis. At this point (2
weeks after surgery), a cervical swab was already positive
on consensus sequences for HPV; however, there was no
evidence of HR HPV infection using qPCR.
In January 2014, 3 months after her operation, she was
admitted to hospital because of significant proteinuria,
1.5 g/24 hours, and increased serum creatinine level of
160 mol/l. A renal biopsy revealed T cell-mediated acute
kidney rejection with borderline changes and focal seg-
mental glomerulosclerosis of graft. She received 20
plasmapheresis sessions and 500 mg of methylpredniso-
lone intravenously three times. Her therapy was successful
and her proteinuria disappeared. Although, during this
immunosuppressive therapy (6 months after operation)
her qPCR results showed a significantly high load of HR
HPV in a cervical swab (3,630,789 copies/105 cells), but it
was not significant in her urine (2691 copies/105 cells).
Specific typing confirmed that it was HPV-18. Expression
of HPV-18 E6 and E7 oncogenes was also found in her
cervical swab.
Because of acute graft rejection, her cyclosporine was
substituted with tacrolimus (Advagraf; Astellas, Japan)
and her initial dose was 6 mg with serum through level
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of 6.3 ng/ml. During this regimen, she showed the most
severe immune system suppression (Fig. 2). Exactly dur-
ing this period (1 year after surgery), her HR HPV-18
viral load in cervical swab (7,413,102 copies/105 cells)
and urine sample (18,620 copies/105 cells) doubled.
Expression of HPV-18 E6 and E7 oncogenes still was de-
tected in cervical swab.
Despite all consultations about pregnancy contraindi-
cation and all risks which were described to her by a
nephrologist and a gynecologist, on 12 November 2014
Fig. 1 Time scale of immunosuppressive therapy and progression of human papillomavirus type 18 infection. HPV human papillomavirus, HR
high-risk, mRNA messenger RNA
Fig. 2 Lymphocyte absolute count changes during three periods of time (6 months, 12 months, and 16 months) depending on changes in
human papillomavirus type 18 load. HPV human papillomavirus, HR high-risk, Ly lymphocyte, mRNA messenger RNA
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she had a positive result on a human chorionic gonado-
tropin (hCG) hormone test for pregnancy. An ultrasound
examination confirmed the presence of a gestational sac at
5 weeks of gestation. She did not tell her nephrologist in
time about her pregnancy and that is why her therapy
with prednisolone, tacrolimus, and mycophenolate mofetil
stayed the same. At the sixth/seventh week of pregnancy
she had a spontaneous abortion.
After her spontaneous abortion (December 2014) she
again had a relapse of proteinuria: 1.5 g/24 hours. She re-
ceived 500 mg of rituximab (MabThera; F. Hoffmann-La
Roche, Switzerland) intravenously and after that she again
started plasmapheresis. This time she received 15 plasma-
pheresis sessions. Her proteinuria decreased from 1.5 g/24
hours to 0.4 g/24 hours and she left hospital for further am-
bulatory observation. Two months after her spontaneous
abortion, we observed a noticeable decrease in her viral
load in a cervical swab (39 copies/105 cells). Moreover, her
urine sample did not show any viral load of HPV-18 and
was negative with consensus primers for HPV sequences.
Expression of E6 and E7 oncogenes was not revealed. At
the same time an increase in almost all her immunocompe-
tent cells parameters was detected (Fig. 2). During the
whole study, we could not detect any IgG antibodies to HR
HPV L1 major capsid’s protein in her plasma.
Discussion
Persistence of HR HPV is strongly associated with the
development of cervical cancer. In addition, several
studies showed that increased viral load can also be a
significant factor to predict progression to high-grade
cervical lesions [7–9]. Renal allograft recipients in par-
ticular are at high risk of developing persistent infection
and HPV-associated cancer [10]. Regression of HPV-
associated infection requires an adequate immune re-
sponse including CD4 and antigen-presenting cells
(APC) infiltrate, response of T helper cells (Th1), tumor
necrosis factor (TNF)-alpha production, and high
CD4:CD8 ratio [11]. Immunosuppressive therapy is act-
ing against all these factors. Prednisolone and methyl-
prednisolone act as nonspecific inhibitors of
macrophage cytokine secretion, including TNF-alpha.
Cyclosporine A and tacrolimus block interleukin (IL)-2
production which is necessary for the activation and
proliferation of T cells. Mycophenolate mofetil also
blocks proliferation of lymphocytes by inhibiting guanine
nucleotide synthesis in lymphocytes [12].
During screening for HPV in renal transplant recipi-
ents, one of the female patients stood out because she
had developed a significantly elevated HR HPV load dur-
ing the strengthening of immunosuppressive therapy.
Initially, she was positive only on HPV consensus
sequences in cervical swab and we could not find any
presence of HR HPV infection neither in cervical swab
nor urine sample. Six months after renal transplantation
she rapidly developed HR HPV-18 infection with clinic-
ally significant viral load which we found in cervical
swab (3,630,789 copies/105 cells) and urine sample (2691
copies/105 cells). Also, mRNA of HPV-18 E6 and E7 on-
cogenes were detected in the cervical swab. Such results
may be explained not only by maintenance of immuno-
suppression therapy with prednisolone, cyclosporine A,
and mycophenolate mofetil but also with recent intra-
venous injections of methylprednisolone, which was
used to treat acute T cell rejection of the graft. After this
event, she received even stronger immunosuppressive
therapy (cyclosporine was substituted with tacrolimus),
which was reflected by a decrease in her immunocompe-
tent cells parameters (Fig. 2). She showed lymphopenia
and her lowest counts of CD3+, CD4+, CD8+, and
CD25+ lymphocyte subpopulations (Fig. 2), and CD4
+/CD8+ ratio during the whole study. This could be a
major factor in the doubling of her HR HPV load
(7,413,102 copies/105 cells) during 1 year after renal
transplantation.
An impressive viral load decrease in cervical swab to
39 copies/105 cells and disappearance of E6 and E7
oncogenes’ mRNA was found 1 year and 4 months after
transplantation. At this time her immune status notice-
ably improved. Her absolute lymphocyte counts grew to
normal ranges. Her count of CD3+ doubled, CD4+ tri-
pled, CD8+ increased 1.6 times, CD25+ tripled, and
CD16+ increased 1.25 times (Fig. 2). It is not fully clear
what factor could influence such a sharp decrease in her
HR HPV load. First, and very obvious, it could be due to
her spontaneous abortion, which provoked physical
damage to epithelial tissue and might have contributed
to viral clearance. The literature has shown that miscar-
riage may be considered a significant factor that can
promote clearance of HPV infection. An earlier study
showed a lower prevalence of HPV DNA in females with
recurrent miscarriage (26.53 %) than in females with at
least one pregnancy at term (61.89 %) [13]. Also it is
possible that the spontaneous abortion caused inflamma-
tion, which could explain the increase in almost all her
immunocompetent cell parameters and this immune
system boost could have contributed to viral clearance
as well. Another factor which could be responsible for
HR HPV clearance is a change in immunosuppressive
therapy regimen because changes in immunosuppressive
drug and dosage might improve immunocompetent cell
parameters. However, the threshold for immunocompe-
tent cell parameters to be considered to be capable to
clear HPV infection is unclear.
A recent study reported that IgG antibodies to L1 capsids
are essential for regression of HPV-induced cervical lesions
and are associated with better prognosis [14]. However,
during our research we could not detect the presence of
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these antibodies in our patient’s plasma. Such a result may
be explained by her immunocompromised status and a lack
of CD19+ lymphocyte subpopulation 12 months and 16
months after renal transplantation. This was caused by the
rituximab, which inhibits activity of B cells, that she re-
ceived 2 weeks before.
In the case of our patient, we observed a noticeable viral
load reduction from 7,413,102 copies/105 cells to 39 cop-
ies/105 cells 2 months after her spontaneous abortion. It
could be considered that the physical impact on cervical
mucosa during spontaneous abortion and related mucosal
inflammation afterwards contributed to the partial expul-
sion of the virus from the host. However, if virus clearance
associated with lack of IgG antibodies to L1 major viral
capsid’s protein is possible, then it may mean that she will
have another viral load increase in the future.
Conclusions
Immunosuppressive therapy, due to its negative efficacy
on immune cell proliferation and immune activity, in-
creases renal transplant recipients’ risk of developing
persistent HR HPV infection with expression of E6 and
E7 oncogenes. However, even during this therapy the
immune status of a recipient can improve and contrib-
ute to a decrease in HPV viral load. Spontaneous abor-
tion can also be considered a possible contributory
factor in HPV clearance.
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